Additionally, the NICHE phase II trial confirmed the modest clinical activity of afatinib in patients with HER2-mutant NSCLC, demonstrating an ORR of 7.7% and a median PFS of 15.9 week [30]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.